RARA and acute myeloid leukemia: PRAME is a dominant repressor of retinoic acid (RA) signaling in melanoma and acute myeloid leukemia (AML) by interaction with the Enhancer of Zeste Homolog 2 (EZH2) and the RA receptor α (RARα) at RA response elements (RAREs) [18, 19].